Weifa ASA announced the launch of Solvivo(R) lozenges. With Solvivo(R) Weifa enters the OTC throat segment, which has had a value growth of 64% last twelve months, and represents a value of NOK 11 million last twelve months (pharmacy purchasing price). The launch will be supported by a solid communications campaign towards the end user, as well as a strong effort in training pharmacy staff. Solvivo(R) is indicated for local symptomatic relief of mild mouth and throat infections in adults and children aged over 6 years. It contains the two active substances amylmetacresol and dichlorobenzyl alcohol, which have antiseptic properties. The product also provides a relieving effect on a sore throat and on difficulty in swallowing. Similar products associated with strong commercial success can be found in many other countries; however, there are no identical products to Solvivo(R) on the Norwegian market. Solvivo(R) comes in packs of 24 lozenges, in flavors of Honey & Lemon and Mint. It will be available through all pharmacy chains from September 15th 2016.